Therapeutic apyrase constructs, apyrase agents, and production methods
AssigneeAPT Therapeutics, Inc.
InventorsRidong Chen, Soon Seog Jeong
Life of this patent
Estimating the term…
Abstract
This invention provides a new class of enhanced apyrases (EN-apyrases) with superior pharmacokinetic, pharmacodynamic, and pharmacochemical properties and which can be purified using simplified procedures. The invention further provides constructs for transforming a cell to produce these EN-apyrases. The EN-apyrase construct comprises sequences encoding a signal sequence, a linker, and a soluble apyrase. Also provided are preparations of apyrases and methods for producing apyrase in culture cells and purification thereof.
Claims18
A composition comprising an EN-apyrase, wherein the EN-apyrase is a soluble CD39L3 or a homolog thereof, which has a homogeneous N-terminus wherein more than 80% of the EN-apyrase molecules and homologs have the same N-terminus beginning with EVLP (positions 20-23 of SEQ ID NO:24) and wherein
- (a) the EN-apyrase has an average isoelectric point in the range of about 3.0 to about 4.5;
- and/or
- (b) the EN-apyrase has an in vivo half life in rabbits or pigs at least twice that of HEK sol-CD39L3-01, measured by apyrase assay,
- wherein the homolog of soluble CD39L3 is a sequence having 1 to 5 conservative substitutions with respect to positions 49-485 of SEQ ID NO:1 and/or is at least 80% identical to positions 49-485 of SEQ ID NO:1, and
- which retains ADP'ase and ATP'ase activity.
Dependencies are inferred from the claim text.